2013年8月29日 星期四

高血壓-fibromuscular dysplasia

動脈化生不良 Fibromuscular dysplasia (FMD)

簡介:
  -a non-inflammatory, nonatherosclerotic disorder that leads to arterial stenosis, occlusion, aneurysm, and dissection.
  -部位:
      -最常見: renal & internal carotid arteries,
      -次常見: vertebral, iliac, subclavian, and visceral arteries.
      -nearly in every arterial bed.

  Disease presentation may vary widely, depending upon the arterial segment involved and the severity of disease.
  Common manifestations:
       -hypertension,
       -TIA, stroke,
       -headache, dizziness, tinnitus, and pulsatile tinnitus (abnormal swooshing sound in ears) [1].

-------------------------------------------------------
臨床表現:
renal FMD
  -Hypertension (最常見於 renal artery FMD)
        -A decrease in renal perfusion activates the renin–angiotensin-aldosterone system, which has direct effects on sodium excretion, sympathetic nerve activity, intrarenal prostaglandin concentrations, and nitric oxide production.
        -These ultimately lead to renovascular hypertension.

  *Thus, renal artery FMD should be suspected, particularly in ->
          women (< 50 y/o), in the following settings:
               -Severe or resistant hypertension,
               -Onset of hypertension before the age of 35 years,
               -sudden rise in blood pressure over a previously stable baseline
               -A significant increase in serum Cr (≥ 0.5 to 1 mg/dL) that occurs after (ACEi) or (ARB) in the absence of an excessive reduction in blood pressure (see "Renal effects of ACE inhibitors in hypertension")
               -A systolic-diastolic epigastric bruit

--------------------------------------------------

DDx:

-most commonly mimic the presentation of fibromuscular dysplasia (FMD) are
    -atherosclerotic vascular disease and
    -vasculitis.

■Both atherosclerosis and FMD may cause renal artery stenosis. Patients with atherosclerosis are usually older and have typical cardiovascular risk factors such as dyslipidemia, diabetes mellitus, and a history of tobacco use, whereas individuals with FMD are usually younger and have fewer cardiovascular risk factors [19]. However, given that FMD can occur in older patients, age alone does not exclude the diagnosis.
Atherosclerosis usually involves the ostial or proximal segments of the arteries, whereas FMD involves the middle or distal segments. In addition, the string of beads appearance is unique to FMD.
Multi-system involvement is observed in both vasculitis and FMD. Unlike patients with a vasculitic process, those with FMD generally will not have associated anemia, thrombocytopenia, or abnormalities of acute phase reactants (eg, erythrocyte sedimentation rate or C-reactive protein) given that it is a non-inflammatory process. An exception might be in the setting of an acute infarction.
Other possibilities that may be initially considered before renal artery FMD is diagnosed include
      -primary hypertension (formerly called "essential" hypertension) and
      -any of the potential causes of secondary hypertension,
      -pulmonary edema due to cardiovascular disease, and
      -slowly progressive CKD.
--------------------------------------------------------

診斷 —
    -the diagnosis is confirmed most frequently by:
          -CTA
          -MRA or
          -duplex ultrasonography, and
          -catheter-based digital subtraction angiography (DSA) (較少用)
 
DSA
    -the reference standard.
    -The performance of noninvasive techniques varies depending upon the involved vascular bed and the expertise of a given institution.
    -extracranial cerebrovascular FMD can be diagnosed with CTA, MRA, or duplex ultrasonography, while
    -mesenteric FMD is usually diagnosed with CTA.
Patients suspected of having FMD should
    -first undergo a noninvasive imaging test (such as duplex ultrasound or CTA) to search for FMD.
    -The choice of test should be based upon local expertise.
    -If the noninvasive test is inconclusive, the patient should undergo DSA provided that the pretest probability of FMD remains high and that an intervention would be performed if FMD were to be diagnosed [19].
Imaging techniques
   -The gold standard for evaluating FMD in the renal artery and other vascular beds is catheter-based DSA, which improves visualization of the arteries by eliminating background soft tissue and bone [19]. However, noninvasive imaging techniques are usually sufficient, and therefore DSA is not commonly performed. The angiographic appearances of the different pathologic lesions are as follows:
----------------------------------------------------------------------
 

結論及建議:

 •It is more common among women and, while initially thought to only occur in the young, may occur at any age.
 •The most often involved arteries are the renal (70 %) and internal carotid and vertebral arteries (約65 %), and less often are the iliac, subclavian, and visceral arteries. (See 'Epidemiology' above.)

•The pathogenesis is uncertain,  genetic factors, hormonal influence, and ischemia may contribute. (See 'Pathogenesis' above.)

•The most common manifestations are hypertension, headache, dizziness, tinnitus, transient ischemic attack, and stroke, but other manifestations may occur, depending upon the arterial segment involved and the severity of disease. (See 'Clinical manifestations' above.)

•The diagnosis of renal artery FMD should be suspected in patients with severe or resistant hypertension and an increase in serum creatinine after initiation of an angiotensin-converting enzyme (ACE) inhibitor or angiotensin II receptor blocker (ARB) (particularly in women under the age of 50), onset of hypertension before the age of 35 years, and a systolic-diastolic epigastric bruit.

 •The conditions that most commonly mimic FMD are atherosclerotic vascular disease and vasculitis. (See 'Differential diagnosis' above.)

 •In patients in whom there is a suspicion for renovascular hypertension, a noninvasive imaging test (such as duplex ultrasound or CTA) should be performed first. The choice of test should be based upon local expertise. If noninvasive tests are inconclusive and pretest probability of FMD is high, the patient should undergo catheter-based digital subtraction arteriography. (See 'Imaging techniques' above.)

 •For patients treated medically, we suggest
                -following BP and serum Cr every 3-4 months, and
                -腎超: kidney size every 6 to 12 months. (See 'Monitoring disease progression' above)
 

2013年8月28日 星期三

甲狀腺癌手術-副甲狀腺自體移質

Parathyroid autotransplantation during thyroidectomy. Results of long-term follow-up.

SUMMARY BACKGROUND DATA:
  Permanent hypoparathyroidism is a recognized complication of thyroidectomy. Operative strategies to prevent this complication include preservation of parathyroid glands in situ and autotransplantation of parathyroid glands resected or devascularized during thyroidectomy.  

METHODS: An analysis of 194 patients having thyroidectomy and simultaneous parathyroid autotransplantation at Barnes Hospital from 1990 to 1994 was performed. Data were collected regarding patient demographics, indication for thyroidectomy, operative procedure, pathologic diagnoses, and postoperative course, including biochemical assessment of parathyroid autograft function.

RESULTS: Of 194 patients having either total, subtotal, or completion thyroidectomy, 104 (54%) experienced a [Ca(+2)]nadir less than or equal to 8.0 mg/dL and had symptoms and signs of hypocalcemia. Parathyroid autotransplantation was successful in 103 (99%) of these 104 cases and resulted in a 1.0% incidence of hypoparathyroidism in this series.

CONCLUSIONS:
  -Although preservation of parathyroid glands in situ is desirable, routine parathyroid autotransplantation during thyroidectomy virtually eliminates postoperative hypoparathyroidism. 
  -Normal parathyroid glands resected or devascularized during thyroidectomy for well-differentiated thyroid carcinoma or benign disease should be transplanted in the sternocleidomastoid muscle.
  -Patients with Multiple Endocrine Neoplasia type 2A should have parathyroid glands resected at the time of thyroidectomy for medullary thyroid carcinoma and transplanted in the nondominant forearm.
  -Postoperative management in most patients after thyroidectomy and parathyroid autotransplantation involves temporary calcium and vitamin D replacement and close biochemical evaluation.
  -This precautionary measure of parathyroid autotransplantation markedly reduces the incidence of permanent postoperative hypoparathyroidism.

2013年8月27日 星期二

高血壓-嗜鉻細胞瘤


定義/特性:
    -catecholamine-secreting tumors
    -會製造,分泌catecholamine (NE > EP, dopamine)的神經節
        1) pheochromocytoma (交感神經節細胞) (位於腎上腺髓質或以外)
        2) paraganglioma (會分泌chatecholamine的副交感神經節) (位於頭頸部副交感神經節之頸動脈體(carotid body), Glomus vagale等)
    - 通常來自腎上腺髓質,
    -在成人: (10%瘤)
        10% 雙側
        10% 腎上腺髓質外的交感神經節之嗜鉻性細胞(chromaffin cells) (extra-adrenal pheochromocytoma or paraganglioma)
        10% 惡性,
        10% 家族或遺傳性
                    familial, MEN 2A/2B, von Hippel-Lindau's syndrome, Neurofibromatosis type I

    *MEN 2A: 甲狀腺髓質癌, 嗜鉻細胞瘤, 副甲狀腺亢進,
                2B: 甲狀腺髓質癌, 嗜鉻細胞瘤, mucosal neuromas/ 腸ganglionneuromatosis, marfanoid 特徵

---------------------------------------------------
臨床:

  5Ps (palpitation, pain (angina, headache, 腹痛), perspiration, pallor, pressure (HTN),
  典型triad: 心悸, 頭痛, 多汗

    -高血壓 (60%: 持續性; 40%:陣發性); 無法解釋之低血壓/休克, 臉色蒼白,
    -心悸/心搏過速, 焦慮, 多汗,
    -頭痛, 高血

 * 嗜鉻細胞瘤急症
        -病人於麻醉, 生產, 懷孕, 腹部觸摸/壓迫時, 腫瘤細胞大量釋出catecholamines, 引發症狀


---------------------------------------------------
診斷: *腫瘤分泌之catecholamine會有起伏, 通常測其代謝物 (如metanephrine, VMA)

 *24h 尿 VMA

   Low risk pt: 24h 尿中 fractionated metanephrine & catecholamine (Se/Sp 90/98%) JCEM 2003
   High risk pt: 血 free metanephrine (Se/Sp 99/89%) JAMA 2002

   1.先停止影響檢驗藥物 (TCA, Alfa or beta-blocker, opiates, histamine, glucagon, methyldopa, clonidine); 避免用顯影劑; 使其休息;
      篩檢:
       -測24h 尿中 fractionated metanephrine & catecholamine (dopamine, EP, NE) 或 VMA (vannillylvandelic acid)
             *測尿中catecholamine比VMA更具診斷價值
            (*測plasma & urine free metanephrines 為最敏感且正確, 較少因壓力造成偽陽性)
          
   2.測24h 血壓變化 (自費)
   3.影像學 (if 抽血,驗尿呈陽性)
         -腎上腺CT, MRI皆可 (若無發現, 須懷疑腎上腺外,可用以下)
          *腎上腺碘131-MIBG or Octreotide scintigraphy (閃爍掃描)


-------------------------------------------------------------------------
治療:

  .手術
     * 術前須 1)服用alfa-blocker ( ± beta-blocker: inderal) 二週, 以避免術後低血壓
                     2) volume expansion (因術後可能低血壓)
  .藥物
   1.  α-阻斷劑
     a.  Phenoxybenzamine(POB)此為 α 受體非競爭性阻斷劑,因此其作用為長效(因須等受體重新製造),因此使用此藥,術後可能產生姿態性低血壓。此外此藥無選擇性,
亦即它阻斷 α 1 及 α 2 受體,presynaptic α 2 可抑制神經釋放副腎上腺素,若將其阻斷可造成反射性心跳過速。
     b.  選擇性 α 1 受體阻斷劑如 prazosin、terazosin (hytrin)(2mg/#)、doxazosin (doxaben),
           -此類藥劑已漸取代前者,因其作用時間較短,又不抑制 α 2,不會造成反射性心跳過速
         hytrin (2mg/#): 初: 0.5# hs, 維持: 0.5-2.5#QD (max 10#/d)
         doxaben (1mg) doxaben XL (4mg) 1-16mg am or pm

    2.鈣離子通道阻斷劑 (Adalat OROS)
        -直接使小動脈平滑肌放鬆, 可對抗副腎上腺素及 NPY 之作用,尤其是長效型鈣離子通道阻斷劑效果不錯,若遇較頑強者可與 α 1 受體阻斷劑併用。
        -此外它並不會使血壓降得太低或姿態性低血壓,因此對陣發性高血壓型之病人相當適合;
        -它也可預防鄰苯二酚胺引起的冠狀動脈痙攣及心肌炎。
        -Nicardipine 可靜脈注射調控手術中高血壓。
     3.  β-阻斷劑在未使用 α-阻斷前為禁忌,因 α 1 造成之血管收縮失去血管擴張 β 2 之對抗,造成高血壓危症,甚至又因 β 阻斷造成肺水腫。
           -它主要用於對抗反射性心跳過速。
           -Abetalol(α及 β 阻斷劑,β 阻斷>α 阻斷)曾被用於嗜鉻細胞瘤,但亦有異常高血壓反應之案例。
      4.  中樞 α 2 協同劑,Clonidine 雖然可抑制神經釋放鄰苯二酚胺,而降低血壓及心跳,但因其有反彈高血壓,故未廣泛應用於嗜鉻細胞瘤之高血壓治療。 

    -嗜鉻細胞瘤引發次發性高血壓經過手術切除後大部分可痊癒,
    -家族性者復發率高達 20~50% ,術後高血壓仍須藥物控制者 25~38%,因此術後之追蹤仍然必要。
    -由於laprascopic 手術之發達,麻醉技術之進步,短效 α 1 阻斷劑之研發,手術前後之併發症及死亡率已大為降低


    -trandate (labetalol) (25mg/amp), 20mg ivd (3min以上), q5', max 200mg
       ->緊急血壓控制後, phenoxybenzamine (alfa-blocker) (10mg/cap) 1# bid, q2-3天增加10mg (max 40mg/d)
    -nitroprusside (50mg/amp) 20 amp (1000mg) in D5W ivd (以錫箔紙包紮避光)
       *由 0.3mg/kg/min開始, 50-60kg=900-1080mg
    -phentolamine (10mg/ml) 1-5mg ivd 3'以上


腎上腺髓質掃描 MIBG Adrenal Medulla Scintigraphy

[前言]
   -腎上腺髓質是一種能分泌兒茶酚胺(catecholamin)激素的細胞(叫做嗜鉻性細胞chromaffin cell)所組成,因為節前神經纖維直接伸到腺體的嗜鉻性細胞,所以此激素的分泌直接受到自主神經的控制。
   -Catecholamine激素主要為腎上腺素 (epinephrine)以及正腎上腺素(norepinephrine),兩種激素均是由tyrosine氨基酸衍生而來,其生化合成的過程是 Tyrosine-->Dopa-->Dopamine-->Norepinephrine-->Epinephrine。
   -當腎 上腺髓質的交感神經受到刺激時會引起腎上腺素和正腎上腺素的大量分泌,其中腎上腺素佔80%而正腎上腺素佔20%。
   -基本上兩種激素對於身體的作用很類似, 可以增加心臟的活動力、引起全身血管收縮以及抑制腸胃道蠕動等等。

在造影所使用的藥劑為MIBG(Metaiodo Benzylguanidine),
   -是一種類似正腎上腺素的藥劑,它會聚積在儲有catecholamine的腎上腺髓質嗜鉻性細胞或是交感神經末鞘內, 對於診斷嗜鉻性細胞瘤有76~100%的敏感度,透過全身掃瞄的技術,更能尋找異位或轉移的嗜鉻性細胞腫瘤如medullary thyroid carcinoma,paragangliomas等等,在臨床上最常用於檢查的便是嗜鉻性細胞瘤,因為腎上腺髓質腫瘤促使兒茶酚胺分泌增加,腎上腺素 (epinephrine,norepinephrine)在血中、尿中濃度均會升高,而引起高血壓,盜汗,心悸,緊張等類似交感神經刺激的症狀。
   -一般嗜 鉻性細胞瘤除原發在兩側腎上腺髓質部外,還會沿著脊椎交感神經系轉移,或多發性的神經腫瘤,因此在檢查時一定要進行全身性的掃瞄才行。
[適應症]
   -診斷嗜鉻性細胞瘤(pheochromocytoma),
   -甲狀腺髓質癌(medullary thyroid carcinoma),
   -亞神經節瘤(paragangliomas):存於交感神經及全身之嗜鉻組織,
   -神經母細胞瘤(neuroblastoma),
   -類癌瘤(carcinoid tumor):位於小腸、闌尾、胃結腸發生之一種界線分明的黃色瘤。

[儀器]
GE HELIX或Varicam使用high energy parallel hole collimator(6號)
[藥劑]
I-131-MIBG 0.5~1 mCi,Lugol's solution。
[掃瞄前準備]
1、病人最好先做血液生化檢查,再來作腎上腺髓質掃描,若是epinephrine,norepinephrine,VMA等兒茶酚胺高者才進行MIBG scan。
2、為預防I-131聚積而傷害甲狀腺,打針前三天要服用Lugol's solution,每天4滴,滴入開水中稀釋服用,一直持續到檢查結束為止。
3、MIBG因為結構類似norepinephrine,必須緩慢注射以免引起高血壓的危險性。
4、去除全身之金屬物品。
5、向受檢者或家屬解釋檢查之目的及詳細流程,希望能全力配合以完成繁瑣的檢查。
[掃瞄方法]
1、於注射MIBG後連續3天進行全身掃瞄,攝影時受檢者躺在掃描床上,收集前後位全身掃瞄(由頭部至膝蓋)的影像。
2、掃瞄時第1天速度設為15cm/min,第2及第3天速度改為10cm/min。
3、全身掃瞄後若有局部對MIBG吸收增加等疑點時,加照局部靜態影像,若於膀胱等位置則加照側面,或以漲尿、排空等相對影像以供參考。
4、收集靜態影像條件為[256*256];counts=200~300K或是20~40min視當時影像強度而定;zoom=1。
5、若有明顯病灶的顯現,要局部定位時可用Tc-99m MDP骨骼掃瞄,Tc-99m DTPA腎臟掃瞄等影像與I-131 MIBG用不同能窗的影像作相加減的處理。。
6、若影像裡腸胃道的活性太高,在掃描前於睡前服用兩顆dulcolax(輕瀉劑)清腸。
7、常與醫師討論影像,決定是否要延長掃瞄的時間或是進一步之處理。
[影像處理]
將所拍攝之影像依前後位置及時間順序排列並加註時間即可。
[其他]
這是一個臨床上並不常見的檢查,但是由於它的高敏感性以及幾乎可達100%的特異性,使得臨床上對於CT以及MRI在腎上腺所見到而無法判定的組織能夠提 供一強而有力的工具。另外在進行檢查前一定要確認受檢者的各項血清生化值,瞭解受檢者的用藥史,停用影響MIBG吸收的藥物,尤其是抗憂鬱症的藥物至少要 停服六星期,並且因為國內並無生產此藥,通常在排定檢查日期到藥物進口至台灣要2~3星期,因此檢查前必須跟受檢者解釋清楚,預先將檢查的時段空出來。
[影像範例]
這是一個嗜鉻性細胞瘤的影像,受檢者於第1天就可以在腹部的左前方見到MIBG聚積的影像,在利用Tc-99m MDP收集骨骼的影像後,與MIBG做影像的相加減,便可以定位出腫瘤的位置。 

---------------------------------------------------------------------------------------------------------------------------

Pheochromocytoma
 
32,M, c/o facial flushing began ffg stressful business meeting; also HA (severe, throbbing)(due to↑BP).
Past yr episodic nausea, perspiration, palpitation, anxiety. Recent obstipation頑固便秘 & wt loss x 5kg for last 8m. Currently asymp. Denies drug use. No medication.  HTN (210/125), N° HR, 
PE: thin, regular rate & rhythm,
↑plasma EP/NE (> 2,000 ng/L) at rest.
Clonidine fails to signif suppress plasma catecholamines;↑glucose (due to↑EP/NE),
UA:↑VMA (vanillylmandelic acid)
 
(* false (+)↑VMA –may be due to –coffee, Tea, chocolate, medications).  CT-abd: large right adrenal masses,
Nuc-MIBG:↑left adrenal activity. (=0.2% of pt w/ HTN. Mc adrenal medullary tumor in adults
a/w 1) MEN IIa (Sipple’s synd (pheoch, medullary thyroid ca, parathyroid adenoma.
      2) MEN IIb (Pheoch, medullary thyroid ca, oral/intestinal ganglioneuromatosis)
      3) von Hippel-Lindau dz 
      4) neurofibromatosis.
Rule of 10’s : 10% malig, bil, extra-adrenal, calcify, familial, children.
(treatable persistent (or transcient) 2° HTN, idiopathic 1° neoplasm of chromaffin cells of adrenal medulla (der fr embryonic neural crest cells) producing EP/NE), may also fr retroperitoneal, pelvic, or cervical chromaffin bodies of sympathetic NS.
Cause transient, paroxysmal↑BP. (in rare instance, may↑ACTHàbil adrenal hyperplasia & Cushing’s synd)
Cx : cardiac & cerebral damage due to malig HTN, cardiomyopathy, CHF, Mets.
 
Tx:
Control BP phenoxybenzamine or prazosin for 1-3 wks prior to surgery.
Liberal自由salt intake wks /a surgery.  To reverse chronic vol contraction.
Beta-blocker  - for arrhythmia.
  Only /p adeq alpha-blockade to↓periph vasc resistance.
Surgical resection (laparoscopic or open)
  Follows alpha-blockade.
*close monitoring –intra- & postOPly.
  To prev profound postresection hypotension (fr periph VD)
 
 =========================================================

惡性或良性 catecholamine-secreting tumors  (pheochromocytoma or paraganglioma) (Williams 12e)

  - 從 clinical,  biochemical,  or  histopathologic  characteristics 來分辨很難.
  - Malignancy  is  rare  in  patients  with  MEN2  or  VHL  syndrome, but it is common in those with familial paraganglioma caused by mutations in SDHB.
  -Patients with SDHB mutations  are  more  likely  to  develop  malignant  disease and  nonparaganglioma  neoplasms  (e.g.,  renal  cell  carcinoma)

預後:
  -轉移處: local tissue invasion, liver, bone, lung, omemtum,  and  lymph  nodes.
  -惡性: 5ySR < 50%, but prognosis is variable:
       -50% -> indolent form, life expectancy of  > 20 yrs,
       -50% -> rapidly progressive dz, death within 1-3 yrs after diagnosis.

治療:
 -先評估  the aggressiveness of tumor behavior.
 -需 multimodality, multidisciplinary,  individualized  approach 來控制 catecholamine-dependent  symptoms,  local  mass effect symptoms.
  -對惡性轉移性pheochromocytoma, 長期藥物治療 也類似於術前準備的藥物.
  -因手術可能造成tumor釋放 massive  catecholamine, ablative therapy 應極小心;
    *除了給 α- and β-blocker,  these  pts  術前通常會另外給 metyrosine.

  -轉移處應盡可能切除以減少 tumor burden.
  -骨轉移疼痛或危及結構功能: external radiotherapy or cryoablation or 手術.
  -肝轉移:
       大且無法切除者: thrombotic therapy
       小轉移: radiofrequency ablation
      -long-acting octreotide has been  beneficial (in selected cases)
   -軟組織lesion (無法切除的): External  radiotherapy.

   -腫瘤局部放療(碘131-MIBG治療劑量) 33% 具  partial &  temporary  responses.
   -Combination化療 (CVD: Cyclophosphamide, Vincristin, Dacarbazine): If  tumor  is considered  aggressive  and  the  patient’s  quality  of  life  is affected.
   -標靶治療: Recent preliminary studies suggest that tyrosine kinase inhibitors (e.g., sunitinib) may have a role in the treatment of metastatic pheochromocytoma.113


CVD 化療
      In a nonrandomized, single-arm trial, the efficacy of chemotherapy with a combination CVD protocol (cyclophosphamide, 750 mg/m 2  body surface area on day 1; vincristine, 1.4 mg/m 2  on day 1; and dacarbazine 600 mg/m 2  on days 1 and 2; repeated every 21 days) was studied in 14 patients
with  malignant  pheochromocytoma.
      This  protocol produced  a  complete  and  partial  response  rate  of  57% (median duration, 21 months; range, 7 to >34).
      Complete and  partial  biochemical  responses  were  seen  in  79%  of patients  (median  duration,  >22  months;  range,  6  to  >35 months).
      All  responding  patients  had  objective  improvement in performance status and blood pressure.
      CVD chemotherapy  can  be  continued  until  the  patient  develops new lesions or there is a significant (e.g., >25%) increase in size  of  known  tumor  sites.
      *因此regimen may induce massive catecholamine release, 故給予 CVD  chemotherapy前, 必須optimally α- and β-blocked.
      *the first cycle of CVD should be completed in the hospital and with close medical observation.
      *Management  of  malignant  pheochromocytoma  can  be frustrating  because  curative  options  are  limited.

113. Joshua AM, Ezzat S, Asa SL, et al. Rationale and evidence for sunitinib in  the  treatment  of  malignant  paraganglioma/pheochromocytoma.  J Clin Endocrinol Metab. 2009;94:5-9.

2013年8月22日 星期四

放射免疫分析 (RIA)

Radioimmunoassay

  TSH, fT4,
  microsomal (TPO) Ab, Tg Ab, TSH R Ab, Tg
  ACTH, cortisol, aldosterone,
  FSH, LH, estradiol, progesterone, testosterone, prolactin
  insulin, C-peptide, IGF-I, IGF-BP3, GAD
  micro-albumin
  CEA, CA-125, CA-199, CA-153, PSA, free PSA,
  PTH
  PRA (Renin plasma activity), PRC (Renin plasma concentration)
  B12, folic acid,
  leptin (瘦蛋白)
 

酮酸中毒


病因:

  -糖尿病poor control
  -酗酒

低磷血症


循環血液中磷酸鹽濃度低於正常而引起的磷代謝紊亂。又稱低磷血症。

表現:
   -溶血、倦怠、軟弱及驚厥。

病因:
  -禁食
  -久服氫氧化鋁、氫氧化鎂或碳酸鋁等類結合劑,
  -糖酵解及碱中毒,
  -甲狀腺功能亢進,
  -維生素D缺乏,
  -某些腎小管疾病(例如范可尼氏症候群Fanconi syndrome),
  -酗酒
  -抗維生素D佝僂病(家族性低磷血症)等。

臨床表現
  -中樞神經系統症狀﹐
     如感覺異常﹑構音障礙﹑反射亢進﹑震顫﹑共濟失調﹑昏迷。
  -血液:
     由於紅血球2﹐3-二磷酸甘油酸減低﹐紅細胞壽命縮短﹐可表現球形紅細胞症﹑溶血。乏力﹐肌肉軟弱﹐肌肉疼痛﹐甚至癱瘓。
     白血球吞噬功能障礙﹐易發生感染。血小板功能障礙﹐血小板聚集能力降低。
  -骨痛(由於骨軟化病)﹐X射線片上可見假骨折。

診斷

  -最常引起低磷酸鹽血症的原因是鹼中毒(呼吸性及代謝性)。

  -通常低磷酸鹽血症可按下列程序進行鑒別﹕
     -先排除呼吸鹼中毒原因後﹐
     -測定尿磷酸鹽
        尿磷酸鹽排泄增加:
            -測定血漿鈣:
                  *血漿鈣增加﹐則考慮原發性副甲狀腺功能亢進﹑異位性副甲狀腺﹐惡性腫瘤
                  *血漿鈣正常或減低﹐則考慮繼發性副甲狀腺功能亢進﹑佝僂病或骨軟化症﹑范可尼氏症候群(Fanconi synd)﹑低磷酸鹽血性軟骨病。
        尿磷酸鹽排泄減少:
           -應考慮飲食中磷酸鹽攝入減少﹑制酸劑治療﹑胰島素治療等。

治療可以靜脈內補液及補磷酸鹽,同時針對病因進行治療。

發病機轉:

   一般飲食中含有充分的磷酸鹽。
  但低磷酸鹽血症可發生在下列情況﹕
     -禁食﹐特別是進行靜脈高營養的病人﹐因葡萄糖可增加細胞對磷酸鹽的攝取﹐導致低磷酸鹽血症。
    -長期服用氫氧化鋁﹑氫氧化鎂或碳酸鋁一類結合劑﹐抑制磷酸鹽的腸腔吸收。
    -糖酵解及碱中毒﹐可迅速消耗細胞內磷酸鹽的濃度﹐增加細胞對磷酸鹽的攝入﹐從而引起低磷酸鹽血症。
    -糖尿病酸中毒病人進行胰島素治療後﹐糖酵解增加﹐磷酸鹽也向細胞內移動。
    -副甲狀腺功能亢進﹐甲狀旁腺素分泌增加﹐使尿磷酸鹽排泄增加。
    -維生素D缺乏﹐減少腸腔磷酸鹽的吸收。
    -某些腎小管疾病﹐如范可尼氏症候群﹐此時尿磷酸鹽排出明顯增加。
    -酗酒﹐由於飲食減少﹑糖酵解增加以及用抗酸結合劑治療胃炎﹐引起低磷酸鹽血症。
    -抗維生素D佝僂病Familial vit D resistant rickets(家族性低磷血症)﹐為性連鎖顯性遺傳病﹐近曲小管磷重吸收障礙﹐腸鈣吸收亦不良。


治療:

-靜脈內補液及補磷酸鹽糾正。
   *常用的磷酸鹽有磷酸二氫鉀(KH2PO4)及磷酸氫二鈉(Na2HPO4)的混合劑。
   *若同時合併高鈣血症﹐為防移位性鈣化形成﹐靜脈補給磷酸鹽應減少。
   *靜脈補給磷酸鹽可引起下列併發症﹕
      -低鈣血症。移位性鈣化形成。
      -醫源性高鉀血症及高鈉血症(補入磷酸鹽引起)。
-針對引起低磷酸鹽血症的原因進行治療。

2013年8月20日 星期二

甲狀腺癌, 碘131治療流程


Thyrogen (0.55mg IM) 3PM on 8/26, 8/27
Thyrotropin (rh-TSH) 1 vial (1.1mg) ST
I-131 (150mCi) therapy on 8/27
check serum TSH, fT4, thyroglobulin


131治療前之準備工作
Ø 了解輻射風險及防護後填寫治療同意書(輻射防護病房住院病患同意書)
Ø 育齡婦女治療前務必排除懷孕的可能性,必要時可驗尿或抽血檢查。
Ø 停用Eltroxin 四至六週或T3藥物兩週(或服用碘131前兩天施打rh-TSH)確保TSH濃度高於30μU/ml
Ø 低碘飲食(一至兩週),可增加放射碘的攝取。
低碘(鹽)飲食。(盡量減少或不要攝取下列食物-高碘; 鹽含多量碘):
- 海菜類及藻纇製品:如海帶、海藻、石花菜、海膠、海生植物、紫菜、海苔…..等。
- 含碘食鹽、海鹽:暫時停止使用一般食鹽,改用無碘鹽(例:台鹽的如意精鹽);減少外食次數;若需外食,請以清淡為原則。
-海鮮類:包含海產、海魚等。
-  醃漬、加工食品:火腿、培根、罐頭製品、蜜餞、醬菜、等。
-  醬油或含紅色素食物
-  麵包類:法國麵包、鬆餅、其他含鹽量較高之麵包。
-  蛋、奶或乳製品(乳酪、起司、冰淇淋等)
-  蔬菜水果類:菠菜、香蕉。
-  藥物:電腦斷層使用的含碘顯影劑、含碘維他命、咳嗽藥水等。
Ø  來院時,請攜帶:

-  飲用水(建議一天飲水至少2000 cc)。
- 可服食味道酸的糖果、蜜餞刺激唾液分泌。

住院前1天9am, 打0.5支 thyrogen; 
住院當天 
   -9:00再打0.5支 thyrogen; 
   -1h 後抽血 (TSH, FT4, Tg); 
   -11am入輻射隔離病房(居家隔離) 服用碘131
住院2nd天休息
3rd天: 碘uptake WBS (whole body scan), 抽血測 Tg, 開始服用eltroxin

碘131 常用劑量: 100-150 mCi  (一生累積劑量max 600 mCi)




131治療後之護理指導

Ø  原則上碘131治療後48小時可恢復甲狀腺素的服用,7-10天後返回門診
接受核子醫學科掃描。
Ø  服用碘131
   -第一週與旁人距離至少一公尺,且時間在一小時內;
   -第二週距離至少一公尺,但時間可增加為二小時;
   -第三、四週則一公尺相處可增加為 四小時。
Ø  出院後注意事項:
-  服用甲狀腺素和止吐藥。
-  出院後一週內:
²  多喝水,常解尿,多洗手。
²  避免和嬰幼兒、兒童、青少年、孕婦過於接近,建議保持至少三公尺的距離。對於大於45歲者,建議也應保持一公尺的距離。
²  若家中有幼兒需要照顧,建議事先請他人代勞。若真的需要見面,盡量保持三公尺距離,且每次相處時間不要超過20分鐘。
²  男性病患建議坐著小便。上完廁所後,馬桶至少沖水三次。如廁後徹底洗手並保持廁所清潔。
²  注意個人清潔衛生。避免汗水、嘔吐物等分泌物污染環境。
²  避免坐飛機和大眾運輸工具,避免長途旅行。避免進出公共場所,如電影院等。
²  避免口對口親吻及性接觸。建議在一年後再懷孕較為安全。
²  不要與他人共用牙刷、毛巾、浴巾、衣物等。建議可與家人分開清洗。
²  建議餐具與家人分開使用及清洗。
²  單獨睡覺。
Ø  強烈建議三星期內不接觸十歲以下孩童或懷孕婦女。
Ø  停止母乳哺餵52天,減少嬰兒由母乳受到輻射線的傷害。